Michael Klichinsky is the co-founder and chief scientific officer of Carisma Therapeutics, which is developing macrophage-based cell therapies for cancer.
November 7, 2023 10:23 AM ESTUpdated 11:53 AM
Cell/Gene Tx
In Focus

mR­NA’s next trick? Re­pro­gram­ming off-the-shelf cell ther­a­pies for can­cer and au­toim­mune dis­eases

Ryan Cross

Senior Science Correspondent

Lei Lei Wu

News Reporter

A hand­ful of biotechs, in­clud­ing Mod­er­na, are bet­ting that sim­ple in­fu­sions with mR­NA could su­per­charge im­mune cells to fight can­cer and oth­er dis­eases in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times